论文部分内容阅读
目的:评估交替放化疗(CRT)对晚期鼻咽癌(NPC)患者的疗效与影响因素。方法:选取在我院耳鼻喉科治疗的102例鼻咽癌患者。交替使用放疗,化疗进行治疗。在102例患者中,83例接受顺铂(50 mg/m2/d,d1-2)和5-氟尿嘧啶(5-Fu;800 mg/m2/d,d1-5),而19例患者接受卡铂(20 mg/m2/d,d6)和5-FU。结果:72(70.6%)例患者完成全部3个化疗疗程。交替放化疗的总时间为92(82-102)天。中位随访时间54个月,5年无进展生存期(PFS)为70.5%。多因素分析显示,体重减轻和化疗疗程数对PFS有显著影响。结论:化疗与放疗交替治疗的NPC患者依从性好,适应性强,值得临床推广。
Objective: To evaluate the efficacy and influential factors of alternating radiotherapy (CRT) in patients with advanced nasopharyngeal carcinoma (NPC). Methods: 102 cases of nasopharyngeal carcinoma treated by otolaryngology in our hospital were selected. Alternate use of radiotherapy, chemotherapy for treatment. Of the 102 patients, 83 received cisplatin (50 mg / m2 / d, d1-2) and 5-fluorouracil (5-Fu; 800 mg / m2 / d, d1-5) Platinum (20 mg / m2 / d, d6) and 5-FU. Results: 72 (70.6%) patients completed all three chemotherapy regimens. The total time for radiotherapy and chemotherapy was 92 (82-102) days. The median follow-up time was 54 months and the 5-year progression-free survival (PFS) was 70.5%. Multivariate analysis showed that weight loss and the number of chemotherapy regimens had a significant effect on PFS. Conclusion: The NPC patients who are treated alternately by chemotherapy and radiotherapy have good compliance and strong adaptability, which is worthy of clinical promotion.